AstraZeneca PLC: How Will Its Expansion In Vaccines & Cell Therapy Play Out?

Based on the Q1 2024 results earnings call for AstraZeneca, the British multinational pharmaceutical and biopharmaceutical company seems to be on a steady growth trajectory, but like all corporations, it’s not without its risks. In terms of its achievements, AstraZeneca reported its first quarter of 2024 with a 19% growth in total revenue, reflecting high demand for its products. Core earnings per share rose by 13%. The revenue growth was most pronounced across AstraZeneca’s therapy areas, with both its Oncology and BioPharma businesses exceeding $5 billion in quarterly revenue for the first time. Rare Disease also exceeded $2 billion, showcasing the high value that AstraZeneca’s medicines bring to patients worldwide.